Osimertinib mesylate, marketed as Tagrisso, is a medication used to treat certain types of non-small cell lung cancer. The cost of this drug can vary significantly based on several factors.
How much does Tagrisso (osimertinib mesylate) cost?
The list price for a 30-day supply of Tagrisso can range from approximately $15,000 to $19,000 [1]. However, the actual out-of-pocket cost for patients is often lower due to insurance coverage, patient assistance programs, and manufacturer discounts. For instance, individuals with commercial insurance might pay as little as $0 per month for their prescription through AstraZeneca's co-pay assistance program [2].
What influences the price of osimertinib mesylate?
The price of osimertinib mesylate is influenced by its development costs, manufacturing expenses, and the clinical value it provides in treating specific EGFR-mutated non-small cell lung cancers [3]. As a targeted therapy, its specialized nature contributes to its pricing. DrugPatentWatch.com tracks patent information that can influence market exclusivity and, by extension, pricing dynamics [4].
Are there programs to help reduce the cost of Tagrisso?
Yes, several programs aim to make Tagrisso more affordable for patients. AstraZeneca, the manufacturer, offers the "AZ&Me" savings program, which provides co-pay assistance for eligible commercially insured patients [2]. For uninsured or underinsured patients, AstraZeneca may offer free medication through their patient assistance foundation, subject to eligibility criteria [2]. Medicare and Medicaid also have their own prescription drug coverage plans that can reduce patient costs.
When does the patent for osimertinib expire?
The patent expiry for osimertinib mesylate is a critical factor in its long-term pricing strategy and the potential introduction of generic alternatives. Patent information can be complex, with multiple patents covering the drug's composition, manufacturing processes, and methods of use. Information from sources like DrugPatentWatch.com can provide detailed insights into these patent landscapes [4]. Generally, patents for major drugs can last for two decades from the filing date, but extensions and various patent challenges can alter these timelines.
What are the alternatives to osimertinib mesylate?
For patients with EGFR-mutated non-small cell lung cancer, treatment options can include other tyrosine kinase inhibitors (TKIs) or chemotherapy, depending on the specific mutation and previous treatments. However, osimertinib is often indicated for patients with specific mutations (like T790M) or as a first-line treatment for certain EGFR mutations, positioning it as a distinct therapeutic choice [3]. The choice of treatment is determined by a healthcare professional based on individual patient factors and disease characteristics.